Teleflex's (TFX) Hold Rating Reiterated at Needham & Company LLC

Teleflex (NYSE:TFX - Get Free Report)'s stock had its "hold" rating reissued by Needham & Company LLC in a research note issued on Wednesday,Benzinga reports.

Several other research analysts have also issued reports on the stock. Piper Sandler reaffirmed a "neutral" rating and issued a $140.00 target price (down previously from $255.00) on shares of Teleflex in a research note on Friday, February 28th. Citizens Jmp cut shares of Teleflex from an "outperform" rating to a "market perform" rating in a research note on Thursday, February 27th. StockNews.com cut shares of Teleflex from a "buy" rating to a "hold" rating in a research report on Friday, February 28th. Wells Fargo & Company reduced their price target on Teleflex from $214.00 to $146.00 and set an "equal weight" rating on the stock in a research report on Friday, February 28th. Finally, Truist Financial decreased their price objective on Teleflex from $200.00 to $149.00 and set a "hold" rating for the company in a research note on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $182.63.

Remove Ads

Teleflex Price Performance

Shares of TFX traded up $1.51 during mid-day trading on Wednesday, hitting $137.79. 900,213 shares of the company traded hands, compared to its average volume of 863,055. The company has a current ratio of 2.42, a quick ratio of 1.39 and a debt-to-equity ratio of 0.37. The business has a 50-day moving average of $166.99 and a 200 day moving average of $197.37. Teleflex has a one year low of $128.55 and a one year high of $249.90. The stock has a market capitalization of $6.39 billion, a price-to-earnings ratio of 27.39, a PEG ratio of 1.73 and a beta of 1.21.

Teleflex (NYSE:TFX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The medical technology company reported $3.89 EPS for the quarter, beating analysts' consensus estimates of $3.86 by $0.03. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. The firm had revenue of $795.40 million for the quarter, compared to analyst estimates of $813.24 million. As a group, equities analysts expect that Teleflex will post 13.98 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Teleflex

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Headlands Technologies LLC acquired a new position in Teleflex during the fourth quarter worth $29,000. Avior Wealth Management LLC grew its stake in Teleflex by 190.6% in the third quarter. Avior Wealth Management LLC now owns 154 shares of the medical technology company's stock valued at $38,000 after purchasing an additional 101 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in shares of Teleflex during the 3rd quarter worth approximately $40,000. True Wealth Design LLC boosted its holdings in shares of Teleflex by 16,600.0% in the 3rd quarter. True Wealth Design LLC now owns 167 shares of the medical technology company's stock valued at $41,000 after buying an additional 166 shares during the last quarter. Finally, IFP Advisors Inc increased its holdings in Teleflex by 238.5% during the fourth quarter. IFP Advisors Inc now owns 308 shares of the medical technology company's stock worth $55,000 after buying an additional 217 shares during the last quarter. Institutional investors and hedge funds own 95.62% of the company's stock.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.